PE20160885A1 - PURINE 2.6 DERIVATIVES SUBSTITUTED IN THE TREATMENT OF PROLIFERATIVE DISORDERS - Google Patents
PURINE 2.6 DERIVATIVES SUBSTITUTED IN THE TREATMENT OF PROLIFERATIVE DISORDERSInfo
- Publication number
- PE20160885A1 PE20160885A1 PE2016000650A PE2016000650A PE20160885A1 PE 20160885 A1 PE20160885 A1 PE 20160885A1 PE 2016000650 A PE2016000650 A PE 2016000650A PE 2016000650 A PE2016000650 A PE 2016000650A PE 20160885 A1 PE20160885 A1 PE 20160885A1
- Authority
- PE
- Peru
- Prior art keywords
- absent
- alkyl
- cycloalkyl
- halogen
- purine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a derivados de purina de formula (I) o sales farmaceuticamente aceptables de los mismos, en los cuales R1 es H, alquilo C1C6, alquenilo C2C6, cicloalquilo C3C6, heteroarilo de 4 a 6 miembros, entre otros; el anillo A es arilo C6C10 o heteroarilo de 5 a 12 miembros; R2 y R5 independientemente estan ausentes o son H, halogeno, CN, CHF2, CF3, alquilo C1C6, cicloalquilo C3C6, entre otros; R3 esta ausente o es H, halogeno, alquilo C1C6, alcoxi C1C6, cicloalquilo C3C6, entre otros; R4 esta ausente o es H, halogeno, alquilo C1C6 o cicloalquilo C3C6; Q esta ausente o es O, S o NH, entre otros; el anillo B esta ausente o es cicloalquilo C3C10, arilo C6C10 o heteroarilo de 5 a 12 miembros, entre otros; R6 y R8 independientemente estan ausentes o son H, halogeno, CN, OH, alquilo C1C3, alcoxi C1C3, entre otros; R7 es GC(O)CH=CH2, GSO2CH=CH2, GC(O)CH2Cl, GC(O)CH2CN, entre otros; G esta ausente cuando el punto de union a B es un atomo de N, o es NR18 cuando el punto de union a B es un atomo de C, donde R18 es H o alquilo C1C3; y m es 0, 1 o 2, con la condicion que m sea 2 cuando el anillo B este ausente. Tambien se refiere a composiciones farmaceuticas que comprenden dichos derivados de purina. Los derivados de purina de formula (I) son utiles para tratar el crecimiento celular anormal en mamiferos, como el cancer.Refers to purine derivatives of formula (I) or pharmaceutically acceptable salts thereof, in which R1 is H, C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, 4- to 6-membered heteroaryl, among others ; ring A is C6-C10 aryl or 5 to 12 membered heteroaryl; R2 and R5 independently are absent or are H, halogen, CN, CHF2, CF3, C1-C6 alkyl, C3-C6 cycloalkyl, among others; R3 is absent or is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, among others; R4 is absent or is H, halogen, C1-C6 alkyl, or C3-C6 cycloalkyl; Q is absent or is O, S or NH, among others; ring B is absent or is C3-C10 cycloalkyl, C6-C10 aryl, or 5- to 12-membered heteroaryl, among others; R6 and R8 independently are absent or are H, halogen, CN, OH, C1-C3 alkyl, C1-C3 alkoxy, among others; R7 is –G–C(O)–CH=CH2, –G–SO2–CH=CH2, –G–C(O)–CH2Cl, –G–C(O)–CH2–CN, among others; G is absent when the point of attachment to B is an N atom, or is NR18 when the point of attachment to B is a C atom, where R18 is H or C1-C3 alkyl; and m is 0, 1 or 2, with the proviso that m is 2 when ring B is absent. It also relates to pharmaceutical compositions comprising said purine derivatives. The purine derivatives of formula (I) are useful for treating abnormal cell growth in mammals, such as cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907322P | 2013-11-21 | 2013-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160885A1 true PE20160885A1 (en) | 2016-09-11 |
Family
ID=52004011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000650A PE20160885A1 (en) | 2013-11-21 | 2014-11-10 | PURINE 2.6 DERIVATIVES SUBSTITUTED IN THE TREATMENT OF PROLIFERATIVE DISORDERS |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9290496B2 (en) |
| EP (1) | EP3071570B1 (en) |
| JP (2) | JP6166845B2 (en) |
| KR (1) | KR101919672B1 (en) |
| CN (1) | CN105916853B (en) |
| AP (1) | AP2016009219A0 (en) |
| AR (1) | AR098492A1 (en) |
| AU (1) | AU2014351433B2 (en) |
| CA (1) | CA2931034C (en) |
| CL (1) | CL2016001151A1 (en) |
| CR (1) | CR20160236A (en) |
| CU (1) | CU24402B1 (en) |
| CY (1) | CY1120478T1 (en) |
| DK (1) | DK3071570T3 (en) |
| DO (1) | DOP2016000115A (en) |
| EA (1) | EA029842B1 (en) |
| ES (1) | ES2681799T3 (en) |
| GE (1) | GEP20186878B (en) |
| GT (1) | GT201600091A (en) |
| HR (1) | HRP20181036T1 (en) |
| HU (1) | HUE039858T2 (en) |
| IL (1) | IL245698B (en) |
| LT (1) | LT3071570T (en) |
| MA (1) | MA39043B1 (en) |
| MD (1) | MD20160053A2 (en) |
| MX (1) | MX2016006397A (en) |
| MY (1) | MY184433A (en) |
| NI (1) | NI201600072A (en) |
| PE (1) | PE20160885A1 (en) |
| PH (1) | PH12016500911A1 (en) |
| PL (1) | PL3071570T3 (en) |
| PT (1) | PT3071570T (en) |
| RS (1) | RS57537B1 (en) |
| SI (1) | SI3071570T1 (en) |
| TN (1) | TN2016000188A1 (en) |
| TW (1) | TWI538913B (en) |
| UA (1) | UA115388C2 (en) |
| UY (1) | UY35845A (en) |
| WO (1) | WO2015075598A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2924362C (en) * | 2013-09-18 | 2018-12-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of btk and/or jak3 kinases |
| AU2016261730A1 (en) * | 2015-05-12 | 2017-11-16 | Zeno Royalties & Milestones, LLC | Bicyclic compounds |
| EP3518925A4 (en) * | 2016-09-30 | 2020-04-15 | SRI International | Dual clk/cdk1 inhibitors for cancer treatment |
| EP3541389A1 (en) | 2016-11-16 | 2019-09-25 | Pfizer Inc | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
| BR112019012682A2 (en) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | chimeric molecules targeting egfr proteolysis and associated methods of use |
| US11312713B2 (en) | 2017-03-10 | 2022-04-26 | Pfizer Inc. | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors |
| WO2018163030A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
| WO2019241896A1 (en) | 2018-06-22 | 2019-12-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Purine compounds and method for the treatment of cancer |
| KR20200105631A (en) * | 2019-02-28 | 2020-09-08 | 보로노이바이오 주식회사 | Heteroaryl comprising N derivatives and pharmaceutical composition containing the same as an active ingredient |
| EP4155304A4 (en) * | 2020-05-20 | 2024-05-29 | TYK Medicines Inc. | Compound used as ret kinase inhibitor and application thereof |
| JP2024533565A (en) | 2021-09-14 | 2024-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 3-Phenoxyazetidin-1-yl-heteroarylpyrrolidine derivatives and their use as medicines - Patents.com |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| EP0821671B1 (en) | 1995-04-20 | 2000-12-27 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DK0780386T3 (en) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | matrix metalloprotease |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN1116286C (en) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4-anilinoquinazoline derivatives |
| US6207669B1 (en) | 1996-07-13 | 2001-03-27 | Glaxo Wellcome Inc. | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| DK0912559T3 (en) | 1996-07-13 | 2003-03-10 | Glaxo Group Ltd | Condensed heterocyclic compounds as protein tyrosine kinase inhibitors |
| TR199900066T2 (en) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matrix metalloprotateazlar�n phosphinate bazl� inhibit�rleri |
| US6790958B2 (en) | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6794390B2 (en) | 1996-08-02 | 2004-09-21 | Cv Therapeutics, Inc. | Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha |
| PL331895A1 (en) | 1996-08-23 | 1999-08-16 | Pfizer | Arylosulphonylamino derivatives of hydroxamic acid |
| US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
| BR9807815A (en) | 1997-02-03 | 2000-03-08 | Pfizer Prod Inc | Arylsulfonylamino-hydroxamic acid derivatives |
| WO1998034915A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| HUP0000657A3 (en) | 1997-02-11 | 2000-10-30 | Pfizer | N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them |
| EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| JP2002501532A (en) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | Novel angiogenesis inhibitors |
| CA2297967A1 (en) | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
| WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | Novel angiogenesis inhibitors |
| EP1028964A1 (en) | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| RS49779B (en) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
| PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
| AU759226B2 (en) | 1998-05-29 | 2003-04-10 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (en) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| EE200200710A (en) | 2000-06-22 | 2004-06-15 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| JP4105948B2 (en) | 2000-09-15 | 2008-06-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrazole compounds useful as protein kinase inhibitors |
| AR042586A1 (en) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
| WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| WO2003009852A1 (en) | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
| US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
| JP2005512972A (en) | 2001-10-12 | 2005-05-12 | アイアールエム エルエルシー | Kinase inhibitor scaffolds and methods for their preparation |
| JP2006512313A (en) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | Anti-inflammatory agent |
| US20070184067A1 (en) | 2003-08-08 | 2007-08-09 | Dusan Miljkovic | Alimentary compositions and methods for metabolic modulation |
| WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| AU2004264419B2 (en) | 2003-08-15 | 2009-01-15 | Irm Llc | 6-substituted anilino purines as RTK inhibitors |
| US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| FR2876583B1 (en) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS |
| GB0502573D0 (en) | 2005-02-08 | 2005-03-16 | Topotarget As | Therapeutic compounds |
| GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| US20070253896A1 (en) | 2006-02-07 | 2007-11-01 | Conforma Therapeutics Corporation | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors |
| CN101438288A (en) | 2006-03-15 | 2009-05-20 | Csir公司 | Regulation of phosphoryl transferase activity of glutamine synthetase |
| SI2076268T1 (en) | 2006-10-19 | 2013-04-30 | Genzyme Corpoartion | Roscovitine for the treatment of certain cystic diseases |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| CN101622001A (en) | 2007-01-26 | 2010-01-06 | Irm责任有限公司 | The purine compound and the compositions that are used for the treatment of plasmodium related diseases as inhibitors of kinases |
| US8404674B2 (en) * | 2007-03-07 | 2013-03-26 | Boehringer Ingelheim International Gmbh | Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof |
| US20090176778A1 (en) | 2007-08-10 | 2009-07-09 | Franz Ulrich Schmitz | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| US20100197914A1 (en) | 2007-10-17 | 2010-08-05 | Robin Alec Fairhurst | Purine Derivatives as Adenosine Al Receptor Ligands |
| US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
| WO2010019392A1 (en) | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Purine derivatives for treatment of alzheimer's disease |
| AR073397A1 (en) * | 2008-09-23 | 2010-11-03 | Palau Pharma Sa | DERIVATIVES OF (R) -3- (N, N-DIMETHYLAMINE) PIRROLIDINE |
| PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
| US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| ES2659725T3 (en) * | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and disorder treatment procedure |
| FR2945747A1 (en) * | 2009-05-25 | 2010-11-26 | Centre Nat Rech Scient | ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING A CDKS INHIBITOR AND A CELL GROWTH INHIBITOR |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| WO2011156889A1 (en) | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| US20130172340A1 (en) | 2010-06-22 | 2013-07-04 | University of Central Flordia Research Foundation, | Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3 |
| EA201390550A1 (en) * | 2010-10-14 | 2013-08-30 | Ариад Фармасьютикалз, Инк. | METHODS OF INHIBITING PROLIFERATION OF CELLS IN EGFR-STIMULATED MALIGNANT TUMORS |
| WO2012061303A1 (en) * | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
| WO2012064706A1 (en) * | 2010-11-10 | 2012-05-18 | Avila Therapeutics, Inc. | Mutant-selective egfr inhibitors and uses thereof |
| JP5999177B2 (en) * | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Compound for inhibiting cell proliferation of EGFR-activated cancer |
| US8762299B1 (en) | 2011-06-27 | 2014-06-24 | Google Inc. | Customized predictive analytical model training |
| EP2758402B9 (en) * | 2011-09-22 | 2016-09-14 | Pfizer Inc | Pyrrolopyrimidine and purine derivatives |
| CN103159742B (en) | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-chloropyrimide compounds and the application as EGFR tyrosine kinase inhibitor thereof |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| CA2904797A1 (en) | 2013-03-14 | 2014-09-18 | Pfizer Inc. | Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer |
| US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
-
2014
- 2014-10-11 UA UAA201605505A patent/UA115388C2/en unknown
- 2014-11-10 PE PE2016000650A patent/PE20160885A1/en unknown
- 2014-11-10 CA CA2931034A patent/CA2931034C/en active Active
- 2014-11-10 EA EA201600337A patent/EA029842B1/en not_active IP Right Cessation
- 2014-11-10 MA MA39043A patent/MA39043B1/en unknown
- 2014-11-10 KR KR1020167016053A patent/KR101919672B1/en active IP Right Grant
- 2014-11-10 AU AU2014351433A patent/AU2014351433B2/en not_active Ceased
- 2014-11-10 MX MX2016006397A patent/MX2016006397A/en unknown
- 2014-11-10 JP JP2016532623A patent/JP6166845B2/en not_active Expired - Fee Related
- 2014-11-10 ES ES14806447.0T patent/ES2681799T3/en active Active
- 2014-11-10 AP AP2016009219A patent/AP2016009219A0/en unknown
- 2014-11-10 MY MYPI2016701796A patent/MY184433A/en unknown
- 2014-11-10 TN TN2016000188A patent/TN2016000188A1/en unknown
- 2014-11-10 PL PL14806447T patent/PL3071570T3/en unknown
- 2014-11-10 GE GEAP201414151A patent/GEP20186878B/en unknown
- 2014-11-10 WO PCT/IB2014/065935 patent/WO2015075598A1/en active Application Filing
- 2014-11-10 PT PT148064470T patent/PT3071570T/en unknown
- 2014-11-10 EP EP14806447.0A patent/EP3071570B1/en active Active
- 2014-11-10 MD MDA20160053A patent/MD20160053A2/en not_active Application Discontinuation
- 2014-11-10 LT LTEP14806447.0T patent/LT3071570T/en unknown
- 2014-11-10 HU HUE14806447A patent/HUE039858T2/en unknown
- 2014-11-10 SI SI201430806T patent/SI3071570T1/en unknown
- 2014-11-10 CU CU2016000073A patent/CU24402B1/en unknown
- 2014-11-10 CN CN201480073530.7A patent/CN105916853B/en active Active
- 2014-11-10 RS RS20180909A patent/RS57537B1/en unknown
- 2014-11-10 DK DK14806447.0T patent/DK3071570T3/en active
- 2014-11-19 UY UY0001035845A patent/UY35845A/en not_active Application Discontinuation
- 2014-11-20 US US14/548,749 patent/US9290496B2/en active Active
- 2014-11-20 TW TW103140297A patent/TWI538913B/en not_active IP Right Cessation
- 2014-11-20 AR ARP140104368A patent/AR098492A1/en unknown
-
2016
- 2016-05-13 CL CL2016001151A patent/CL2016001151A1/en unknown
- 2016-05-17 PH PH12016500911A patent/PH12016500911A1/en unknown
- 2016-05-18 IL IL24569816A patent/IL245698B/en active IP Right Grant
- 2016-05-19 DO DO2016000115A patent/DOP2016000115A/en unknown
- 2016-05-20 GT GT201600091A patent/GT201600091A/en unknown
- 2016-05-20 CR CR20160236A patent/CR20160236A/en unknown
- 2016-05-20 NI NI201600072A patent/NI201600072A/en unknown
-
2017
- 2017-06-23 JP JP2017122759A patent/JP2017214390A/en active Pending
-
2018
- 2018-07-05 HR HRP20181036TT patent/HRP20181036T1/en unknown
- 2018-07-25 CY CY20181100779T patent/CY1120478T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160885A1 (en) | PURINE 2.6 DERIVATIVES SUBSTITUTED IN THE TREATMENT OF PROLIFERATIVE DISORDERS | |
| CY1122712T1 (en) | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | |
| CY1124737T1 (en) | LPA COMPETITORS | |
| CY1121901T1 (en) | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | |
| CY1122821T1 (en) | 1,3-BENZODIOXOLE DERIVATIVES AS EZE1 AND/OR EZE2 INHIBITORS | |
| CL2020001546A1 (en) | 4-azaindole compounds. | |
| AR106763A1 (en) | OXADIAZOLS REPLACED TO FIGHT FITOPATHOGEN FUNGI | |
| UY37900A (en) | NEW DERIVATIVES OF RAPAMYCIN | |
| CR20170118A (en) | SPIRODIAMINE DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA | |
| CY1124537T1 (en) | PYRIDONE DERIVATIVE HAVING A TETRAHYDROPYRANYL METHYL GROUP | |
| CR20160241A (en) | NEW DIHYDROCHINOLIZINONES FOR THE TREATMENT AND PROFILAXIS OF VIRUS INFECTION OF HEPATITIS B | |
| CU24517B1 (en) | SUBSTITUTE CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTINEOPLASTIC AGENTS | |
| DOP2016000299A (en) | PIRROLIDINE-2,5-DIONA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND ITS USE AS IDO1 INHIBITORS | |
| NI201600007A (en) | N, 6-BIS (ARYL OR HETEROARYL) -1,3,5-TRIAZIN-2,4-DIAMINE COMPOUNDS AS MUTANT IDH2 INHIBITORS FOR THE TREATMENT OF CANCER. | |
| CR20150509A (en) | USEFUL NAFTIRIDINE DERIVATIVES AS ANTAGONISTS OF THE ALFA-V-BETA-6 INTEGRINE | |
| CR20160140A (en) | DERIVATIVES OF QUINOLIZINE SUBSTITUTED USEFUL AS INHIBITORS OF HIV INTEGRASA | |
| CR20160337A (en) | NEW HETEROARILDIHYDROPIRIMIDINES 6-FUSIONATED FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | |
| PE20181145A1 (en) | PYRIDINE COMPOUNDS | |
| PE20180483A1 (en) | OXIESTEROLS AND METHODS OF USE OF THE SAME | |
| UA115354C2 (en) | New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| AR095311A1 (en) | 3-PIRIMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS MUTANT HDI INHIBITORS | |
| PE20180024A1 (en) | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | |
| AR098171A1 (en) | PIRIDINILIMIDAZOLONAS AS HERBICIDES | |
| ECSP17057131A (en) | DEACETOXITUBULISIN H AND ANALOGUES OF IT | |
| BR112019007980A2 (en) | method for producing 3-alkylsulfanyl-2-chloro-n- (1-alkyl-1h-tetrazol-5-yl) -4-trifluoromethyl-benzamides |